CSII - FibroGen hurt by downgrades Danaher given Street-high target - today's analyst action

Mario13/E+ via Getty Images FibroGen courts downgrades after FDA setback for Roxadustat  FibroGen (FGEN) has lost ~35.7% in the pre-market in reaction to its failure to win the endorsement from FDA’s expert panel for Roxadustat in anemia due to chronic kidney disease ((CKD)). The setback has triggered Several downgrades from Wall Street. Bank of America analysts led by Jason Gerberry see no path for the therapy in the U.S. market. With no U.S. royalties for the drug co-developed by the company with AstraZeneca, the analysts downgrade the stock to neutral from buy. The price target slashed to $29.00 from $43.00 per share implies a premium of ~16.7%. Meanwhile, Stifel analyst Annabel Samimy who has lowered the recommendation to hold from buy has also trimmed its per share target to $29.00 from $55.00. Late last month, FibroGen won the positive opinion from the European Medicines Agency ((EMA)) for Roxadustat to treat anemia due to

For further details see:

FibroGen hurt by downgrades, Danaher given Street-high target - today's analyst action